🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Awesome talk by co-fellow Sahil Doshi MSK Department of Medicine reporting data from a multi-institution cohort to evaluate first line systemic therapy options in the 1st line treatment of metastatic chromophobe RCC. Really important data in a rare disease where clinical trial data are

Just Out on The Lancet Oncology New findings from the PROSPER EA8143 trial Perioperative nivolumab before nephrectomy, followed by adjuvant nivolumab ➡️Primary endpoint was investigator-reviewed recurrence-free survival ➡️Did NOT🚫improve recurrence-free survival vs surgery only

Our paper on liver TACE and immunotherapy in RCC is now online. Great job by Jeffrey Schneider Mark C. Markowski Orthopaedic Anonymous americanjir.com/transarterial-… via @https://twitter.com/AmericanJIR

#TiNivo2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! PRNEWS Targeted Oncology OncLive.com KidneyCAN Kidney Cancer Uromigos Oncology Brothers —implications beyond renal cancer ?

Can’t miss! The The Oncologist #KCRS24 abstract supplement is out! 🔗 bit.ly/KCRS24Abstract #KidneyCancer #RCC #AcceleratingCures OncoAlert Toni Choueiri, MD Hans Hammers Sumanta K. Pal, MD, FASCO Rana McKay, MD, FASCO ari hakimi Yüksel Ürün

Special shout out to co-surgeons Ying-Wei Lum William Burns Hopkins Surgery and med onc Yasserged Johns Hopkins Kimmel Cancer Center So fortunate to be part of the A-team for our patients Johns Hopkins Medicine! Great production by The Johns Hopkins Brady Urological Institute Hopkins Med News highlighting Chris’s story Testicular Cancer Testicular Cancer Society

Lots to learn from this and other ongoing trials in papillary kidney cancer. S1500 and others show us that it’s possible — please consider this trial for all your patients with this disease.

Special thanks to Drs. Steven Schenkel & Kristin Walter JAMA and Mary L. (Nora) Disis JAMA Oncology for the unique opportunity, & to coauthors DrBagrodia Christian D. Fankhauser Yasserged Ezra Baraban! Johns Hopkins Medicine The Johns Hopkins Brady Urological Institute Amer. Urol. Assn. Society of Urologic Oncology European Association of Urology (EAU) Testicular Cancer Testicular Cancer Society

Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatment outcomes in this rare entity. journals.lww.com/immunotherapy-… nirm Sumanta K. Pal, MD, FASCO Ritesh Kotecha Matthew Zibelman

1/7 Pleased to share updated OS results from the #TIVO-3 study (NCT02627963), previously presented at #ESMO24. Our analysis focused on outcomes in patients with #ccRCC who had received prior treatment with a checkpoint inhibitor (CPI) - representing 26% of the trial population.

🚨 New AI Tool for Immunotherapy Prediction! 🧠💊 A deep learning model predicts response to ICI in advanced NSCLC using H&E pathology slides! 🏥🔬 ✅ Outperforms biomarkers like PD-L1 & TMB ✅ May improve selection for immunotherapy ✅ Hope to see in other tumor types!

Ab#437 ASCO #GU25 by Wenxin (Vincent) Xu👉 bit.ly/3CLElIk👉post-hoc analysis of CheckMate214 #kidneycancer👉⬆️KIM-1 associated w/⬇️OS & KIM-1 reduction correlates w/⬆️ Ipi+Nivo efficacy👇 OncoAlert UroToday.com Uromigos Kidney Cancer KidneyCAN

Congratulations, Dr. Noah Hahn of Johns Hopkins Kimmel Cancer Center and all co-authors on presentation of ADAPT-BLADDER (HCRN-GU16-243) Cohort 4 results at #GU25.

It’s an honor to present my poster at #ASCOGU. Sharing our findings on the impact of Area Deprivation Index on Immunotherapy outcomes in mRCC. Stop by poster D13 to discuss! #CancerResearch #ASCOGU25

Our new study in JITC introduces a dual ERV-based stratification system for predicting immunotherapy efficacy in metastatic ccRCC patients. The model outperforms traditional transcriptomic signatures, offering enhanced precision for ICI treatment outcomes. Journal for ImmunoTherapy of Cancer 🙏Xiaofan Lu

We report a new role for HIF in the regulation of endogenous retroviruses! It was a big collaborative effort to explore the HIF-mediated transcription, expression, and HLA presentation of ERVs in kidney cancer and leveraging them for immunotherapy cell.com/cell/fulltext/…

💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫 nirm DrBagrodia  Dr #EzraBaraban Yale Pathology Christian D. Fankhauser Yasserged JAMA OncoAlert 💡 Key Insights: 🧬 Epidemiology & Risk Factors 🔹 Most common solid malignancy in men aged 15-40 🔹 ~10,000 cases

Looking forward to a great line-up with GU onc experts from The Johns Hopkins Brady Urological Institute Johns Hopkins Kimmel Cancer Center Johns Hopkins Medicine Sibley Hospital JHM featuring Yasserged Cathy Handy Marshall, MD MPH Jean Hoffman-Censits Armine Smith & Mohit Narang. Dinner and great networking opportunity. Thank you MJH Life Sciences® OncLive.com !